Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP02 - Health Services Research/Health Economics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Health Services Research/Health Economics
-
+
FP02.02 - Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US
00:00 - 00:00 | Presenter: Alex I. Spira
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.06 - CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
00:00 - 00:00 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P77.02 - Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading...
-
+
P90 - Targeted Therapy - Clinically Focused - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P90.03 - A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
00:00 - 00:00 | Presenter: Alex I. Spira
- Abstract
Loading...
-
+
OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
10:30 - 10:40 | Presenter: Alex I. Spira
- Abstract
Loading...
-
+
OA04 - New Data from Rare EGFR Alterations
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Targeted Therapy - Clinically Focused
-
+
OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
11:55 - 12:05 | Presenter: Joshua K. Sabari
- Abstract
Loading...
-
+
PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS01.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer
07:50 - 08:00 | Presenter: Bob T. Li
- Abstract
Loading...
-
+
PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)
- 18:00 - 20:00
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PS02.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer
18:50 - 19:00 | Presenter: Bob T. Li
- Abstract
Loading...
